Health
ERS Genomics and Applied StemCell sign agreement on commercialization of CRISPR gene editing tools – News-Medical.net
ERS Genomics Limited, which was formed to provide broad access to the foundational CRISPR/Cas9 intellectual property (IP) co-owned by Dr. Emmanuelle Charpentier, today announced it has signed an agreement with Applied StemCell, Inc., a leading provider of ste…
ERS Genomics Limited, which was formed to provide broad access to the foundational CRISPR/Cas9 intellectual property (IP) co-owned by Dr. Emmanuelle Charpentier, today announced it has signed an agreement with Applied StemCell, Inc., a leading provider of stem cell, animal model, antibody discovery services and reagents.
ERS Genomics holds an exclusive worldwide license from Dr. Charpentier to the foundational patents covering CRISPR/Cas9. Companies can obtain licenses to this technology for in…
-
Noosa News21 hours agoNRL grand final quick hits: Reece Walsh creates magic after avoiding sin bin as Broncos survive Hunt, Reynolds injuries to win premiership
-
General21 hours agoHow the internet reacted to Brisbane Broncos winning the NRL grand final
-
Noosa News12 hours agoNew playground equipment encourages children to learn through ‘risky play’
-
General10 hours agoThree youths in police custody after fire at Ashley Youth Detention Centre in northern Tasmania